| Identification | Back Directory | [Name]
6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-CYCLOPROPYL]-NICOTINIC ACID | [CAS]
153559-76-3 | [Synonyms]
LG 268
CD 3127
ALRT 268
lg100268
LGD 1268
LGD 100268
AGN 192620
hthalenyl)cyclopropyl)-
3-pyridinecarboxylicacid,6-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-nap
6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-CYCLOPROPYL]-NICOTINIC ACID
2-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)cyclopropyl]pyridine-5-carboxylic acid
6-[1-(3,5,5,8,8-PentaMethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
3-Pyridinecarboxylicacid,6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentaMethyl-2-naphthalenyl)cyclopropyl]-
6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]- 3-Pyridinecarboxylic Acid
6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-CYCLOPROPYL]-NICOTINIC ACID (FOR R&D ONLY) | [Molecular Formula]
C24H29NO2 | [MDL Number]
MFCD01758574 | [MOL File]
153559-76-3.mol | [Molecular Weight]
363.49 |
| Chemical Properties | Back Directory | [Appearance]
Off-White Solid | [Melting point ]
275-277°C | [Boiling point ]
487.0±33.0 °C(Predicted) | [density ]
1.115±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO: ≥5mg/mL (warmed) | [form ]
powder | [pka]
2.35±0.10(Predicted) | [color ]
white to beige | [InChI]
1S/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27) | [InChIKey]
SLXTWXQUEZSSTJ-UHFFFAOYSA-N | [SMILES]
Cc1cc2c(cc1C3(CC3)c4ccc(cn4)C(O)=O)C(C)(C)CCC2(C)C |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
LG 100268 is a potent RXR agonist for evaluation in the treatment of non-insulin-dependent (type II) diabetes mellitus (NIDDM). | [Biochem/physiol Actions]
LG100268 (LG268) is a potent and selective rexinoid and retinoid-X receptor (RXR) agonist. LG100268 binds to the α, β and γ RXR receptors with an IC50 = 3-4 nM and has no activity at the RAR retinoic acid receptors. | [in vivo]
LG100268 (oral diet; 100 mg/kg; once daily; 7 weeks) combines with C/P presents a more markedly reduced average tumor burden than LG268 or C/P alone. The combination establish a reduced lung tumors, which represents a reduction of 82% (vs. 59%-67% with the single drugs) in comparison with the controls[3]. | Animal Model: | A/J mice[3] | | Dosage: | 50 mg/kg (Combines with carboplatin (50 mg/kg i.p.) starts 1 week after the LG268 treatment diet) | | Administration: | Oral diet; once daily; 7 weeks | | Result: | Decreased lung tumors growth significantly in mice. |
| [storage]
Store at -20°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|